PMC8024092_01
(a) Sinus CT before the administration of mepolizumab. CT shows fluid and mucosal thickening in the maxillary sinuses on both sides, predominantly on the right. (b) Sinus CT in 6 months after the administration of mepolizumab. CT shows a decrease in fluid and mucosal thickening of the maxillary sinuses on both sides.
CRIRH2021-5561762.001.jpg
PMC8024092_01_CRIRH2021-5561762.001.jpg
fig1
Sinus computed tomography (CT) showed maxillary sinusitis and mild ethmoid sinusitis and sphenoid sinusitis, and the Lund-Mackay CT score was 10 points (Figure 1(a)). A significant improvement was seen in the clinical symptoms associated with CRS, the eosinophil count, the MPO-ANCA titer, and the sinus radiological findings after 6 months of mepolizumab therapy, and the Lund-Mackay CT score dropped to 3 points (Figure 1(b) and Figure 2).
Clinical course. MPO-ANCA: myeloperoxidase-antineutrophil cytoplasmic antibody.
CRIRH2021-5561762.002.jpg
PMC8024092_01_CRIRH2021-5561762.002.jpg
fig2
A significant improvement was seen in the clinical symptoms associated with CRS, the eosinophil count, the MPO-ANCA titer, and the sinus radiological findings after 6 months of mepolizumab therapy, and the Lund-Mackay CT score dropped to 3 points (Figure 1(b) and Figure 2). Furthermore, even after mepolizumab was tapered to 200 mg every 4 weeks, her condition remained stable without relapse of EGPA and without increases in the eosinophil count and the MPO-ANCA titer (Figure 2).